Natrunix 400 mg + Placebo + Methotrexate (MTX)

Phase 2Recruiting
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Jul 15, 2026 → Jul 15, 2027

About Natrunix 400 mg + Placebo + Methotrexate (MTX)

Natrunix 400 mg + Placebo + Methotrexate (MTX) is a phase 2 stage product being developed by XBiotech for Rheumatoid Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06590090. Target conditions include Rheumatoid Arthritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06590090Phase 2Recruiting

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
TilmanoceptNavidea BiopharmaceuticalsPhase 1
25
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
44
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
77
LY2127399Eli LillyPhase 3
77
Baricitinib + TNF InhibitorEli LillyApproved
85
CT-P17 SC AI (adalimumab)CelltrionPhase 3
77
Remsima IV + Remsima SCCelltrionPre-clinical
23
CT-P13 + RemicadeCelltrionPhase 3
77
CT-P47 + EU-approved RoActemraCelltrionPhase 3
77
InfliximabCelltrionPhase 3
77
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Rituximab, MTX, folic acidCelltrionPhase 1
33
CT-P10 + Rituxan + MabTheraCelltrionPhase 3
77
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)CelltrionPhase 3
77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 3
77
rituximabCelltrionPhase 1
33
CT-P17 SC + Humira SCCelltrionPhase 3
77
AdalimumabCelltrionPre-clinical
23
InfliximabCelltrionPhase 3
77